Luteolin induced G2 phase cell cycle arrest and apoptosis on non-small cell lung cancer cells. 2011

Xueting Cai, and Tingmei Ye, and Chao Liu, and Wuguang Lu, and Min Lu, and Juan Zhang, and Min Wang, and Peng Cao
School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, Jiangsu, China.

In this study, we investigated the underlying molecular mechanism for the potent cell cycle inhibition and pro-apoptotic effect of luteolin (2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-chromenone) on human non-small-cell lung carcinoma cell line A549. MTT assay showed that luteolin had obvious cytotoxicity on A549 with IC(50) of 40.2 μM at 48 h. Pro-apoptotic effect of luteolin on A549 cells was demonstrated by Hoechst 33258 staining assay and annexin V-FITC/PI double staining analysis. A great quantity of apoptotic cells and increasing G2 phase cells were observed by flow cytometry. Western blotting assay revealed that luteolin activated JNK, increased Bax, promoted procaspase-9 cleavage and activated caspase-3 at last. Assay using TNFα, an active agent of NF-κB, showed that pretreatment of A549 cells with luteolin could inhibit TNFα induced trans-nuclear of NF-κB. In summary, luteolin displayed a significant cytotoxic effect through cell cycle arrest and apoptosis induction in A549 cells. Pro-apoptotic effect was implemented via activating JNK and inhibiting translocation of NF-κB (p65). These results suggested that luteolin might have therapeutic potential against NSCLC.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005456 Fluorescent Dyes Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. Flourescent Agent,Fluorescent Dye,Fluorescent Probe,Fluorescent Probes,Fluorochrome,Fluorochromes,Fluorogenic Substrates,Fluorescence Agents,Fluorescent Agents,Fluorogenic Substrate,Agents, Fluorescence,Agents, Fluorescent,Dyes, Fluorescent,Probes, Fluorescent,Substrates, Fluorogenic
D006690 Bisbenzimidazole A benzimidazole antifilarial agent; it is fluorescent when it binds to certain nucleotides in DNA, thus providing a tool for the study of DNA replication; it also interferes with mitosis. Bisbenzimide,4-(5-(4-Methyl-1-piperazinyl)(2,5'-bi-1H-benzimidazol)-2'-yl)phenol, trihydrochloride,Bisbenzimidazole Trihydrochloride,Hoe-33258,Hoechst 33258,NSC-322921,Pibenzimol,Hoe 33258,Hoe33258,NSC 322921,NSC322921
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic

Related Publications

Xueting Cai, and Tingmei Ye, and Chao Liu, and Wuguang Lu, and Min Lu, and Juan Zhang, and Min Wang, and Peng Cao
July 2018, European journal of pharmacology,
Xueting Cai, and Tingmei Ye, and Chao Liu, and Wuguang Lu, and Min Lu, and Juan Zhang, and Min Wang, and Peng Cao
January 2020, Cancer control : journal of the Moffitt Cancer Center,
Xueting Cai, and Tingmei Ye, and Chao Liu, and Wuguang Lu, and Min Lu, and Juan Zhang, and Min Wang, and Peng Cao
March 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Xueting Cai, and Tingmei Ye, and Chao Liu, and Wuguang Lu, and Min Lu, and Juan Zhang, and Min Wang, and Peng Cao
August 2004, Cancer letters,
Xueting Cai, and Tingmei Ye, and Chao Liu, and Wuguang Lu, and Min Lu, and Juan Zhang, and Min Wang, and Peng Cao
October 2015, Pharmacognosy magazine,
Xueting Cai, and Tingmei Ye, and Chao Liu, and Wuguang Lu, and Min Lu, and Juan Zhang, and Min Wang, and Peng Cao
January 2010, Bioscience, biotechnology, and biochemistry,
Xueting Cai, and Tingmei Ye, and Chao Liu, and Wuguang Lu, and Min Lu, and Juan Zhang, and Min Wang, and Peng Cao
January 2024, Current molecular medicine,
Xueting Cai, and Tingmei Ye, and Chao Liu, and Wuguang Lu, and Min Lu, and Juan Zhang, and Min Wang, and Peng Cao
September 2016, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Xueting Cai, and Tingmei Ye, and Chao Liu, and Wuguang Lu, and Min Lu, and Juan Zhang, and Min Wang, and Peng Cao
August 2020, Chemico-biological interactions,
Xueting Cai, and Tingmei Ye, and Chao Liu, and Wuguang Lu, and Min Lu, and Juan Zhang, and Min Wang, and Peng Cao
November 2007, Cancer letters,
Copied contents to your clipboard!